Onco-Innovations Limited (NEO:ONCO)

Onco-Innovations Income Statement

Financials in millions CAD. Fiscal year is May - April.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023
Revenue	0.07	-	-
Gross Profit	0.07	-	-
Selling, General & Admin	1.32	0.39	0
Research & Development	0.24	-	-
Operating Expenses	3.14	0.39	0
Operating Income	-3.07	-0.39	-0
Currency Exchange Gain (Loss)	-0.01	-	-
Other Non Operating Income (Expenses)	-1.63	-	-
EBT Excluding Unusual Items	-4.71	-0.39	-0
Impairment of Goodwill	-3.66	-	-
Other Unusual Items	-0.13	-	-
Pretax Income	-8.49	-0.39	-0
Net Income	-8.49	-0.39	-0
Net Income to Common	-8.49	-0.39	-0
Shares Outstanding (Basic)	35	3	-
Shares Outstanding (Diluted)	35	3	-
Shares Change (YoY)	905.82%	-	-
EPS (Basic)	-0.24	-0.11	-
EPS (Diluted)	-0.24	-0.11	-
Gross Margin	100.00%	-	-
Operating Margin	-4702.26%	-	-
Profit Margin	-13010.36%	-	-
EBIT	-3.07	-0.39	-0

Source: S&P Global Market Intelligence. Standard template. Financial Sources.